[Report] Generic Series Market Research ,Trends, Analysis TOC

CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the report
  - Methodology
- Key findings
  - Number of generic entrants increased over time with more successful brands experiencing greater levels of competition
  - Branded drugs faced revenue erosion of up to 45% after two years of generic competition
  - Generic prices declined rapidly in the free pricing markets of the US and UK as well as in Germany
  - Summary key trends
CHAPTER 2 INFLUENCE OF PRODUCT AND MARKET SPECIFIC CHARACTERISTICS AT PATENT EXPIRY
- Overview of the impact of generic drugs on branded drug franchises
  - Branded manufacturers faced competition from on average nine generic entrants, after two years of generic competition
  - Branded drugs in the UK and Germany experienced the highest levels brand value erosion
    - Brand erosion - volume versus value
    - Brand erosion across the US and 5EU
  - While brand prices remained flat following generic entry, generic prices in the US, Germany and UK gradually declined
    - Branded drug price following generic entry
    - Generic drug price following generic entry
CHAPTER 3 FORMULATION SPECIFIC BRAND EROSION
- Introduction
  - Number of generic entrants per formulation type
    - Standard oral drugs faced competition from nine generic entrants after two years of generic competition
    - The level of generic competition for branded injectable drugs varies by country
    - The level of generic competition for branded topical drugs in the US remained flat following generic entry
    - The majority of generic entrants target standard oral formulations due to their ease of production, low cost and high usage
  - Level of brand value and volume erosion per formulation type
    - Branded standard oral drugs experience the greatest level of erosion in the US
    - Branded injectable drugs experienced the greatest level of erosion in Germany
    - Branded oral long-lasting drugs did not experience erosion by generic standard oral formulations
    - Branded topical drug revenues declined by 40% after two years of generic competition
    - Standard oral tablets experienced a greater level of brand erosion than alternative formulations in the US
  - Price of generic drugs per formulation type
    - Price of standard oral generics declined by 12% after two years of generic competition
    - Price of generic injectables declined by nearly one-third after two years of generic competition
    - Price of topical generics declined by 21% after two years of generic competition
    - Price of standard oral generics declined more rapidly in the US and Germany than in the other EU markets
  - Price of branded drugs per formulation type following generic entry
    - Brand prices of standard oral drugs declined by 30% after generic entry in Italy, while brand prices in other markets remained flat
    - Brand prices of injectable drugs declined by 8% after two years of generic competition
    - Brand prices of topical drugs continued to grow following generic entry if reformulation strategies are employed
    - Oral brand prices increased the least compared to other formulations following generic entry
CHAPTER 4 IMPACT OF GENERIC EROSION BY BRAND VALUE
- Introduction
  - Brand erosion by revenue size in the US market
    - Brands with higher revenues faced a greater number of generic competitors in the US market
    - Branded drugs that are not protected by an effective LCM strategy experienced a severe decline in revenues following patent expiry
    - Relative generic prices were comparable across each brand value group, and declined to a similar extent over time
    - US summary trends
  - Brand erosion by revenue size in the French market
    - Brands faced greater generic competition over time in the French market
    - Relative generic prices remained flat in France due to the high mandatory discount on market entry
    - French summary trends
  - Brand erosion by revenue size in the German market
    - Brands with higher revenues faced a greater number of generic competitors in the German market
    - Brands with higher revenues face greater generic erosion in the German market
    - The higher the brand value of the drug, the greater the level and speed of generic price reductions
    - German summary trends
  - Brand erosion by revenue size in the Italian market
    - Brands in the $10-50m value group faced the greatest number of generic entrants in Italy
    - Branded drugs with technologically advanced delivery systems are more difficult for generics manufacturers to replicate, providing secure brand protection
    - Relative generic prices remained flat due to the high mandatory discount on market entry, limiting generic drug profit margins
    - Italian summary trends
  - Brand erosion by revenue size in the Spanish market
    - Brands with higher revenues faced a greater number of generic competitors in the Spanish market
    - Level of brand erosion following generic entry was equivalent for all brand value groups in the Spanish market
    - Relative generic prices remained flat due to the high mandatory discount on market entry, limiting generic drug profit margins
    - Spanish summary trends
  - Brand erosion by revenue size in the UK market
    - Brands with higher revenues faced a greater number of generic competitors in the UK market
    - Level of brand erosion following generic entry was equivalent for all brand value groups in the UK market
    - Relative generic prices were comparable across each brand value group, and decline to a similar extent over time
    - UK summary trends
CHAPTER 5 BIBLIOGRAPHY
- Publications and online articles
- Datamonitor reports
- Suggested reading
- Glossary of terms
APPENDIX
- List of Tables
  - Table 1: Overview of the impact of generics on branded drug franchises across the US and 5EU markets (2003-06) with eight quarters of IMS data
  - Table 2: Level of brand franchise volume erosion compared to revenue erosion (2003-06)
  - Table 3: Relative price of branded franchise drug versus generic ($)
  - Table 4: Pharmaceutical products analyzed for this report - US
  - Table 5: Pharmaceutical products analyzed for this report - France
  - Table 6: Pharmaceutical products analyzed for this report - Germany
  - Table 7: Pharmaceutical products analyzed for this report - Italy
  - Table 8: Pharmaceutical products analyzed for this report - Spain
  - Table 9: Pharmaceutical products analyzed for this report - UK
- List of Figures
  - Figure 1: There is a strong correlation between declining generic drug prices and the level of brand erosion after two years of generic incursion
  - Figure 2: Prices of generics by formulation during the first two years following patent expiry compared to branded drug price one quarter prior to patent expiry in the US and 5EU
  - Figure 3: Key summary trends across the US and 5EU markets (2003-06)
  - Figure 4: Average number of generic companies entering the market following a drug patent expiry
  - Figure 5: Incentives for generic prescription in Germany
  - Figure 6: Number of generic companies entering the US and German market following a drug patent expiry
  - Figure 7: Branded drug franchise volume (SU) and value ($) following generic entry (%)
  - Figure 8: Price of brand and generic drugs in Spain and Italy following generic entry
  - Figure 9: Price of brand and generic drugs in France, Germany, the UK and US following generic entry
  - Figure 10: Disincentives for generic prescription in Italy and Spain
  - Figure 11: Average branded and generic drug price following generic entry compared to branded drug price one quarter prior to patent expiry
  - Figure 12: Incentives for generic prescription in the UK
  - Figure 13: Incentives for generic prescription in France
  - Figure 14: Average number of standard oral generic drugs entering the market following a drug patent expiry
  - Figure 15: Average number of injectable generic drugs entering the market following a drug patent expiry
  - Figure 16: Average number of topical generic drugs entering the market following a drug patent expiry
  - Figure 17: Average number of injectable, oral and topical generic drugs entering the market following a drug patent expiry across the US and 5EU markets
  - Figure 18: Revenue shares of leading generics companies by drug formulation in 2006
  - Figure 19: Branded standard oral drug volume (SU) and value ($) following generic entry (%)
  - Figure 20: Incentives for generic prescription in the US
  - Figure 21: Total branded injectable drug volume (SU) and value ($) following generic entry of any formulation (%)
  - Figure 22: Branded injectable drug volume (SU) and value ($) facing direct competition by generic injectables (%)
  - Figure 23: Branded topical drug volume (SU) and value ($) following generic entry (%)
  - Figure 24: Branded drug value ($) erosion by formulation following generic entry (%) in the 5EU and US
  - Figure 25: Branded drug formulation and volume (SU) following generic entry (%) in the 5EU and US
  - Figure 26: Average generic drug price of standard oral drugs following generic entry compared to branded drug price one quarter prior to patent expiry
  - Figure 27: Average generic drug price of injectable drugs following generic entry compared to branded drug price one quarter prior to patent expiry
  - Figure 28: Volume and relative price of brand and generic version of mitoxantrone (injectable) in Italy
  - Figure 29: Average generic drug price of topical drugs following generic entry compared to branded drug price one quarter prior to patent expiry in the US
  - Figure 30: Prices of generics by formulation during the first two years following patent expiry compared to branded drug price one quarter prior to patent expiry in the US and 5EU
  - Figure 31: Average branded standard oral drug price following generic entry compared to branded drug price one quarter prior to patent expiry
  - Figure 32: Average branded injectable drug price following generic entry compared to branded drug price one quarter prior to patent expiry
  - Figure 33: Average branded topical drug price following generic entry compared to branded drug price one quarter prior to patent expiry
  - Figure 34: Average branded standard oral drug price following generic entry compared to branded drug price one quarter prior to patent expiry
  - Figure 35: Average number of generic drugs entering the market following a drug patent expiry in the US, by brand value
  - Figure 36: Branded drug volume (SU) and value ($) following generic entry (%) in the US, by brand value
  - Figure 37: Generic erosion of blockbuster drugs following patent expiry: Merck' s Zocor (simvastatin) and Forest' s Celexa (citalopram).
  - Figure 38: Average branded and generic drug price following generic entry compared to branded drug price one quarter prior to patent expiry in the US, by brand value
  - Figure 39: US summary trends
  - Figure 40: Average number of generic drugs entering the market following a drug patent expiry in France, by brand value
  - Figure 41: Branded drug volume (SU) and value ($) following generic entry (%) in France, by brand value
  - Figure 42: Average branded and generic drug price following generic entry compared to branded drug price one quarter prior to patent expiry in France, by brand value
  - Figure 43: French summary trends
  - Figure 44: Average number of generic drugs entering the market following drug patent expiry in Germany, by brand value
  - Figure 45: Vytorin re-energizes Zocor' s declining German franchise
  - Figure 46: Branded drug volume (SU) and value ($) following generic entry (%) in Germany, by brand value
  - Figure 47: Average branded and generic drug price following generic entry compared to branded drug price one quarter prior to patent expiry in Germany, by brand value
  - Figure 48: German summary trends
  - Figure 49: Average number of generic drugs entering the market following a drug patent expiry in Italy, by brand value
  - Figure 50: Branded drug volume (SU) and value ($) following generic entry (%) in Italy, by brand value
  - Figure 51: Average branded and generic drug price following generic entry compared to branded drug price one quarter prior to patent expiry in Italy, by brand value
  - Figure 52: Italian summary trends
  - Figure 53: Average number of generic drugs entering the market following a drug patent expiry in Spain, by brand value
  - Figure 54: Branded drug volume (SU) and value ($) following generic entry (%) in Spain, by brand value
  - Figure 55: Average branded and generic drug price following generic entry compared to branded drug price one quarter prior to patent expiry in Spain, by brand value
  - Figure 56: Spanish summary trends
  - Figure 57: Average number of generic drugs entering the market following a drug patent expiry in the UK, by brand value
  - Figure 58: Branded drug volume (SU) and value ($) following generic entry (%) in the UK, by brand value
  - Figure 59: Average branded and generic drug price following generic entry compared to branded drug price one quarter prior to patent expiry in the UK, by brand value
  - Figure 60: UK summary trends

Generic Series: Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion at Patent Expiry

Table of Contents